StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.96+0.00 (0.00%)

Close on Nov 18, 2026Market cap $1.31BP/E –Yield –

Novavax revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Novavax's revenue for the twelve months ending Jun 30, 2026 was $413.80M, down 61.6% year over year. For fiscal 2025 it was $1.12B, up 64.7% from the year before. Over ten years it grew 41.0% a year on average. The highest annual figure on record is $1.98B in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.12B+64.7%
FY2024Dec 31, 2024$682.16M-30.7%
FY2023Dec 31, 2023$983.71M-50.4%
FY2022Dec 31, 2022$1.98B+72.9%
FY2021Dec 31, 2021$1.15B+141.0%
FY2020Dec 31, 2020$475.60M+2448.5%
FY2019Dec 31, 2019$18.66M-45.6%
FY2018Dec 31, 2018$34.29M+10.0%
FY2017Dec 31, 2017$31.18M+103.1%
FY2016Dec 31, 2016$15.35M-57.6%
FY2015Dec 31, 2015$36.25M+18.2%
FY2014Dec 31, 2014$30.66M+46.6%
FY2013Dec 31, 2013$20.92M-5.3%
FY2012Dec 31, 2012$22.08M+50.3%
FY2011Dec 31, 2011$14.69M+4182.2%
FY2010Dec 31, 2010$343.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$56.70M-76.3%
Q1 FY2026Mar 31, 2026$139.51M-79.1%
Q4 FY2025Dec 31, 2025$147.14M+66.6%
Q3 FY2025Sep 30, 2025$70.45M-16.6%
Q2 FY2025Jun 30, 2025$239.24M-42.4%
Q1 FY2025Mar 31, 2025$666.66M+610.3%
Q4 FY2024Dec 31, 2024$88.31M-69.7%
Q3 FY2024Sep 30, 2024$84.51M-54.8%
Q2 FY2024Jun 30, 2024$415.48M-2.1%
Q1 FY2024Mar 31, 2024$93.86M+15.9%
Q4 FY2023Dec 31, 2023$291.34M-18.5%
Q3 FY2023Sep 30, 2023$186.99M-74.5%
Q2 FY2023Jun 30, 2023$424.43M+128.3%
Q1 FY2023Mar 31, 2023$80.95M-88.5%
Q4 FY2022Dec 31, 2022$357.40M+60.8%
Q3 FY2022Sep 30, 2022$734.58M+310.7%
Q2 FY2022Jun 30, 2022$185.93M-37.6%
Q1 FY2022Mar 31, 2022$703.97M+57.4%
Q4 FY2021Dec 31, 2021$222.20M-20.5%
Q3 FY2021Sep 30, 2021$178.84M+13.9%
Q2 FY2021Jun 30, 2021$298.02M+738.6%
Q1 FY2021Mar 31, 2021$447.23M+13143.4%
Q4 FY2020Dec 31, 2020$279.66M+3072.2%
Q3 FY2020Sep 30, 2020$157.02M+6163.4%
Q2 FY2020Jun 30, 2020$35.54M+958.6%
Q1 FY2020Mar 31, 2020$3.38M-15.2%
Q4 FY2019Dec 31, 2019$8.82M+43.9%
Q3 FY2019Sep 30, 2019$2.51M-67.6%
Q2 FY2019Jun 30, 2019$3.36M-68.8%
Q1 FY2019Mar 31, 2019$3.98M-58.7%
Q4 FY2018Dec 31, 2018$6.13M-41.2%
Q3 FY2018Sep 30, 2018$7.74M-7.4%
Q2 FY2018Jun 30, 2018$10.77M+60.0%
Q1 FY2018Mar 31, 2018$9.65M+69.9%
Q4 FY2017Dec 31, 2017$10.41M+92.9%
Q3 FY2017Sep 30, 2017$8.35M+158.5%
Q2 FY2017Jun 30, 2017$6.73M–
Q1 FY2017Mar 31, 2017$5.68M–
Q4 FY2016Dec 31, 2016$5.40M–
Q3 FY2016Sep 30, 2016$3.23M–

More Novavax figures

See a number that looks wrong?